Study of YK012 in Primary Membranous Nephropathy

Summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (PMN).

Timeline

Start

2025-03-08

Primary completion

2026-12

Completion

2027-12

Drugs

Indications